TrialA Study of ABC294640 Alone and in Combination With HCQ Sulfate in the Treatment of Advanced Cholangiocarcinoma
Trial details
- Registry ID
- NCT03377179
- Phase
- Phase 2
RDHL
RedHill Biopharma Limited
Company identity has not yet been verified
Browse linked trials and recorded changes, or follow this company for updates.
4Trials in this database
0Recorded changes · last 12 months
Partial coverageOnly the trials and history collected so far
Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.
Completion dates · Pro
Which trial dates moved later?
Pro summarizes how far estimated completion dates moved later and counts trials with edits to their main study measures, using the history available here. View Pro features
Included trials
Check company identity source| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| A Study of ABC294640 Alone and in Combination With HCQ Sulfate in the Treatment of Advanced CholangiocarcinomaNCT03377179 | RedHill Biopharma Limited | Phase 2 | Completed | 2022-06-21Actual |
| Opaganib, a Sphingosine Kinase-2 (SK2) Inhibitor in COVID-19 PneumoniaNCT04467840 | RedHill Biopharma Limited | Phase 2, Phase 3 | Completed | 2021-07-18Actual |
| RHB-204 for the Treatment of Pulmonary Mycobacterium Avium Complex DiseaseNCT04616924 | RedHill Biopharma Limited | Phase 3 | Terminated | 2023-08-28Actual |
| Upamostat, a Serine Protease Inhibitor, or Placebo for Treatment of COVID-19 DiseaseNCT04723537 | RedHill Biopharma Limited | Phase 2, Phase 3 | Terminated | 2021-12-28Actual |
Opaganib, a Sphingosine Kinase-2 (SK2) Inhibitor in COVID-19 Pneumonia
Trial details
- Registry ID
- NCT04467840
- Phase
- Phase 2, Phase 3
RHB-204 for the Treatment of Pulmonary Mycobacterium Avium Complex Disease
Trial details
- Registry ID
- NCT04616924
- Phase
- Phase 3
Upamostat, a Serine Protease Inhibitor, or Placebo for Treatment of COVID-19 Disease
Trial details
- Registry ID
- NCT04723537
- Phase
- Phase 2, Phase 3
Latest recorded trial changes
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.